|
|
|
|
|
|
By GlobalData | Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections. | |
|
|
| CDMOs Evolve IT Validation Strategies To Stay Ahead | Article | Andelyn Biosciences | CDMOs are modernizing IT validation by adopting risk-based, lifecycle approaches, digital tools, and continuous assurance models to improve compliance, efficiency, scalability, and data integrity. |
|
|
|
|
|
| Strategic Approaches On The Path To GMP Manufacture | Q&A | Avid Bioservices | Tech transfer is a critical opportunity to establish a strategy for process performance qualification, mitigate late-stage obstacles, and streamline the pathway to clinical and commercial production. |
|
|
|
| Streamline Your Manufacturing With Development And CDMO Compatibility | White Paper | By Robin Dothager, Jing Huang, Henry Hymas, et al., Thermo Fisher Scientific Bioproduction | Though the journey to mAb development begins at lab scale, for clinical trials and commercial distribution, a production process must be streamlined and scalable to 2,000 L production and above. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|